Fresenius SE & Co. KGaA

Equities

FRE

DE0005785604

Healthcare Facilities & Services

Real-time Estimate Tradegate Other stock markets 09:32:25 2024-04-24 am EDT			5-day change	1st Jan Change
27.52 ^EUR	-0.49%		+3.77%	-2.00%

02:11pm	FRESENIUS SE : Warburg Research reiterates its Buy rating	ZD
Apr. 23	FRESENIUS SE : Goldman Sachs sticks Neutral	ZD

Fresenius : Kabi launches IV Drug in the U.S.

August 30, 2019 at 10:32 am EDT

Phenylephrine Hydrochloride Injection is the latest addition to the company´s growing anesthesia and analgesia portfolio.

Attachments

Original document
Permalink

Disclaimer

Fresenius SE & Co. KGaA published this content on 30 August 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 August 2019 14:31:06 UTC

Latest news about Fresenius SE & Co. KGaA

FRESENIUS SE : Warburg Research reiterates its Buy rating	08:11am	ZD
FRESENIUS SE : Goldman Sachs sticks Neutral	Apr. 23	ZD
Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA.	Apr. 22	CI
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading	Apr. 22	MT
FRESENIUS SE : Receives a Buy rating from Jefferies	Apr. 22	ZD
Barclays reads 'Overweight' for Fresenius SE - Target 35 Euro	Apr. 22	DP
FRESENIUS SE : Barclays reiterates its Buy rating	Apr. 22	ZD
FRESENIUS SE : Berenberg keeps its Buy rating	Apr. 22	ZD
Positive trend of FMC and Fresenius continues	Apr. 22	DP
FRESENIUS SE : Gets a Neutral rating from JP Morgan	Apr. 18	ZD
Lauterbach wants to press ahead with hospital reform despite differences	Apr. 17	DP
State report warns of risks in hospital reform	Apr. 17	DP
FRESENIUS SE : Deutsche Bank maintains a Buy rating	Apr. 17	ZD
Warnings against cutbacks in hospital reform	Apr. 17	DP
Federal and state governments to discuss hospital reform again	Apr. 17	DP
FRESENIUS SE : Gets a Buy rating from Deutsche Bank	Apr. 16	ZD
STOXX 600 nears six-week low on geopolitical jitters; Ericsson shines	Apr. 16	RE
Fresenius at a two-month high - Tyenne launch and fantasy figures	Apr. 16	DP
Fresenius at two-month high - Tyenne launch a milestone	Apr. 16	DP
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Cannabis law and clinic atlas in the Bundesrat	Mar. 22	DP
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
Criticism of hospital reform: 'Redistribution from the bottom to the top'	Mar. 20	DP
European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading	Mar. 19	MT

Chart Fresenius SE & Co. KGaA

Duration

Period

More charts

Company Profile

Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).

Sector

Healthcare Facilities & Services

Calendar

2024-05-07 - Q1 2024 Earnings Call

Related indices

STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST

More Strategies

Ratings for Fresenius SE & Co. KGaA

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.66 EUR

Average target price

36.22 EUR

Spread / Average Target

+30.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
FRESENIUS SE & CO. KGAA	-2.00%	16.67B
CVS HEALTH CORPORATION	-13.25%	86.34B
HCA HEALTHCARE, INC.	+18.01%	84.49B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.97%	29.68B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.50%	17.5B
QUEST DIAGNOSTICS INCORPORATED	-0.86%	15.18B
EUROFINS SCIENTIFIC SE	-1.09%	12.71B
FRESENIUS MEDICAL CARE AG	+3.48%	12.53B
PURE HEALTH HOLDING	-30.53%	11.89B
DAVITA INC.	+27.83%	11.74B

Other Healthcare Facilities & Services